CompletedPhase 3

Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function

France329 participantsStarted 2014-12-11

Plain-language summary

Prospective, multicenter, randomized and open label study evaluating the benefit on renal function at 12 months post-transplantation, with an immunosuppression without calcineurin inhibitor at 3 months and combining mycophenolate sodium-Everolimus versus an immunosuppression combining Everolimus-Tacrolimus, in de novo renal transplant patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients receiving a first kidney transplant from a cadaveric or living donor Exclusion Criteria: * Double transplant * Patient who has been treated with an immunosuppressive drug or study drug during the four weeks before administration of the first dose of Everolimus

What they're measuring

Renal function as measured by estimated glomerular filtration rate GFR

Timeframe: One year after inclusion

Trial details

NCT IDNCT02334488

SponsorPoitiers University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-05-31

View on ClinicalTrials.gov More Chronic Kidney Disease trials